Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours

Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours

Submitted by admin on March 31, 2023 - 10:22am
Source: 
Clinical Trials Arena
News Tags: 
Bolt Biotherapeutics
BDC-1001
solid tumors
Roche
Bristol Myers Squibb
Headline: 
Positive topline data for Bolt’s BDC-1001 in HER2 solid tumours
snippet: 

BDC-1001 will be further investigated in several Phase II programmes in collaboration with BMS and Roche.

Do Not Allow Advertisers to Use My Personal information